The stock of Juno Therapeutics Inc (NASDAQ:JUNO) is a huge mover today! The stock decreased 24.50% or $7.32 on November 23, hitting $22.56. About 17.58 million shares traded hands or 1112.41% up from the average. Juno Therapeutics Inc (NASDAQ:JUNO) has declined 49.28% since April 22, 2016 and is downtrending. It has underperformed by 54.69% the S&P500.
The move comes after 5 months negative chart setup for the $2.27 billion company. It was reported on Nov, 24 by Barchart.com. We have $21.43 PT which if reached, will make NASDAQ:JUNO worth $113.50 million less.
Analysts await Juno Therapeutics Inc (NASDAQ:JUNO) to report earnings on March, 6. They expect $-0.66 earnings per share, down 22.22% or $0.12 from last year’s $-0.54 per share. After $-0.58 actual earnings per share reported by Juno Therapeutics Inc for the previous quarter, Wall Street now forecasts 13.79% negative EPS growth.
Juno Therapeutics Inc (NASDAQ:JUNO) Ratings Coverage
Out of 9 analysts covering Juno Therapeutics Inc (NASDAQ:JUNO), 6 rate it a “Buy”, 0 “Sell”, while 3 “Hold”. This means 67% are positive. $73 is the highest target while $30 is the lowest. The $47.10 average target is 108.78% above today’s ($22.56) stock price. Juno Therapeutics Inc has been the topic of 20 analyst reports since July 22, 2015 according to StockzIntelligence Inc. Citigroup initiated Juno Therapeutics Inc (NASDAQ:JUNO) on Thursday, February 25 with “Buy” rating. The stock of Juno Therapeutics Inc (NASDAQ:JUNO) earned “Buy” rating by Maxim Group on Wednesday, November 23. The company was downgraded on Wednesday, November 23 by FBR Capital. As per Friday, July 8, the company rating was downgraded by JP Morgan. Barclays Capital initiated Juno Therapeutics Inc (NASDAQ:JUNO) on Wednesday, July 6 with “Equal-Weight” rating. The company was initiated on Wednesday, November 18 by Goldman Sachs. Standpoint Research initiated the shares of JUNO in a report on Monday, August 24 with “Buy” rating. The firm has “Hold” rating by Standpoint Research given on Thursday, October 29. The firm earned “Buy” rating on Friday, January 29 by Suntrust Robinson. Maxim Group maintained Juno Therapeutics Inc (NASDAQ:JUNO) rating on Friday, August 5. Maxim Group has “Buy” rating and $50 price target.
According to Zacks Investment Research, “Juno Therapeutics, Inc. is a biopharmaceutical company. The Company develops cellular immunotherapies based on two platforms – Chimeric Antigen Receptors (CARs) and T Cell Receptors (TCRs) technologies. Its clinical CD19 product candidates include JCAR015 that is in Phase I clinical trials for adult patients with relapsed/refractory B cell acute lymphoblastic leukemia (r/r ALL); JCAR017, which is in Phase I/II trials for pediatric patients with r/r ALL whose cancer has recurred after a bone marrow transplant; and JCAR014 that is in Phase I/II trials to treat various B cell malignancies in patients relapsed or refractory to standard therapies. Juno Therapeutics, Inc. is headquartered in Seattle, Washington.”
Insitutional Activity: The institutional sentiment increased to 1.4 in 2016 Q2. Its up 0.06, from 1.34 in 2016Q1. The ratio is positive, as 25 funds sold all Juno Therapeutics Inc shares owned while 36 reduced positions. 23 funds bought stakes while 59 increased positions. They now own 44.56 million shares or 5.68% more from 42.17 million shares in 2016Q1.
Savings Bank Of America Corporation De last reported 39,016 shares in the company. Winfield, a Ohio-based fund reported 20 shares. Blackrock Fund Advsrs has 0.02% invested in the company for 1.96M shares. Mitsubishi Ufj Trust & Banking last reported 959,230 shares in the company. Jane Street Gp Lc holds 17,599 shares or 0% of its portfolio. California State Teachers Retirement Systems accumulated 133,205 shares or 0.01% of the stock. Creative Planning, a Kansas-based fund reported 29,740 shares. Bamco Inc holds 0.02% of its portfolio in Juno Therapeutics Inc (NASDAQ:JUNO) for 100,525 shares. Blackrock Institutional Trust Company Na, a California-based fund reported 1.66 million shares. Voya Management has invested 0% of its portfolio in Juno Therapeutics Inc (NASDAQ:JUNO). Federated Invsts Pa holds 0% of its portfolio in Juno Therapeutics Inc (NASDAQ:JUNO) for 27,614 shares. Raymond James Financial Service Advsr Incorporated has invested 0% of its portfolio in Juno Therapeutics Inc (NASDAQ:JUNO). Goldman Sachs Group Inc Inc, a New York-based fund reported 330,423 shares. Rock Springs Mgmt Lp, a Maryland-based fund reported 197,001 shares. Profund reported 39,877 shares or 0.07% of all its holdings.
More important recent Juno Therapeutics Inc (NASDAQ:JUNO) news were published by: Fool.com which released: “Why Juno Therapeutics Inc Plummeted Today” on November 23, 2016, also Marketwatch.com published article titled: “UPDATE: Juno Therapeutics plummets 30% in pre-market trade after two patient …”, Nasdaq.com published: “Mid-Afternoon Market Update: Caleres Rises On Earnings Beat; Juno Therapeutics …” on November 23, 2016. More interesting news about Juno Therapeutics Inc (NASDAQ:JUNO) was released by: Fool.com and their article: “Better Buy: Ziopharm Oncology, Inc. vs. Juno Therapeutics” with publication date: November 03, 2016.
JUNO Company Profile
Juno Therapeutics, Inc. (Juno), incorporated on August 5, 2013, is a biopharmaceutical firm focused on re-engaging the bodyâ€™s immune system to revolutionize the treatment of cancer. The Firm is developing cell cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells. Juno’s product candidates, JCAR015, JCAR017 and JCAR014, utilize CAR technology to target CD19, a protein expressed on the surface of various B cell leukemias and lymphomas. The Company’s CAR and TCR technologies alter T cells ex vivo, or outside the body. In addition, the Company holds license to vipadenant, a small molecule adenosine A2a (A2a) receptor antagonist that has the potential to disrupt important immunosuppressive pathways in the tumor microenvironment in certain cancers.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.